/ /

Ilana Cass, MD
Dr. Cass is an Assistant Professor of Obstetrics and Gynecology, UCLA/Cedars-Sinai Medical Center, Los Angeles, Calif.
Cervical cancer screening and prevention 2016
Expert commentary on Practice Bulletin No. 157: Cervical Cancer Screening and Prevention
Why are ob/gyns burning out?
Issues with work-life balance, reimbursement, and time are contributors.
Update on BRCA and ovarian cancer
What are the current recommendations for managing women who are BRCA 1 or 2 carriers?
Surgical options for reducing risk in BRCA mutation carriers
Surgical options for reducing risk in BRCA mutation carriers
Among BRCA mutation carriers, risk-reducing bilateral salpingo-oophorectomy (RRSO) results in an 80% reduction in risk of ovarian cancer and a 50% reduction in risk of breast cancer if the surgery is performed before the onset of menopause.
Commentary: Recent updates on power morcellator debate
On November 25, the Food and Drug Agency (FDA) issued a warning against the use of laparoscopic power morcellators in the management of many women undergoing hysterectomy or myomectomy.
BRCA1 and BRCA2: Genetic testing and intervention strategies
Who should undergo genetic testing? Before ordering it, three conditions should be met: There should be a greater than 10% likelihood of a positive test; the ordering physician should be able to interpret the result; and the information should be used to make management decisions.